Recursion Pharmaceuticals reported mixed Q2 results, with revenue falling to $7.67 million, while net loss narrowed to $131.01 million. The company highlighted significant clinical milestones and ...

They say everything is bigger in Texas, and if you take into account all that the state has to offer, it's easy to see why the Lone Star State packs such a potent punch with travelers. Texas is filled ...

A 7-step guide to jump-start your investing journey Peter Gratton, Ph.D., is a New Orleans-based editor and professor with over 20 years of experience in investing, economics, and public policy. Peter ...

Recursion Pharmaceuticals, Inc. is a clinical-stage biotechnology company that combines automation, artificial intelligence, machine learning, and in vivo validation capabilities to discover novel ...

Thank you for reporting this station. We will review the data in question. You are about to report this weather station for bad data. Please select the information that is incorrect.

Thank you for reporting this station. We will review the data in question. You are about to report this weather station for bad data. Please select the information that is incorrect.